Core Points - MannKind Corporation, in partnership with Alfred E. Mann Charities and The Diabetes Link, launched the Centennial Al Mann Scholarship to honor the legacy of its founder Alfred E. Mann, distributing $100,000 in scholarship funds to support young adults living with diabetes pursuing higher education in life sciences [1][2][8] - The scholarship program aims to empower students aged 18-22 with type 1 or type 2 diabetes, providing up to $10,000 per recipient, distributed in annual installments of $2,500 [3][4] - The initiative reflects Alfred E. Mann's commitment to improving human life through medical advancement and philanthropy, continuing his vision of giving back to the community [2][5] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions, particularly in cardiometabolic and orphan lung diseases [6][7] - The company has a history of developing breakthrough medical devices and treatments, including the inhaled insulin product Afrezza, which was brought to market with a significant investment of nearly $1 billion by Alfred E. Mann [5][6] Partnership and Community Impact - The partnership with The Diabetes Link aims to expand access to higher education for young adults with diabetes, addressing the rising costs of college and easing financial burdens [5][12] - The Diabetes Link is a national nonprofit organization dedicated to empowering young adults living with diabetes through peer support and resources, envisioning a future where they thrive in their personal and professional lives [12]
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes